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It is imperative to understand the specific and shared etiologies of major depression
and cardio-metabolic disease, as both traits are frequently comorbid and each repre-
sents a major burden to society. This study examined whether there is a genetic asso-
ciation between major depression and cardio-metabolic traits and if this association is
stratified by age at onset for major depression. Polygenic risk scores analysis and
linkage disequilibrium score regression was performed to examine whether differ-
ences in shared genetic etiology exist between depression case control status
(N cases = 40,940, N controls = 67,532), earlier (N = 15,844), and later onset depres-
sion (N = 15,800) with body mass index, coronary artery disease, stroke, and type
2 diabetes in 11 data sets from the Psychiatric Genomics Consortium, Generation
Scotland, and UK Biobank. All cardio-metabolic polygenic risk scores were associated
with depression status. Significant genetic correlations were found between depres-
sion and body mass index, coronary artery disease, and type 2 diabetes. Higher poly-
genic risk for body mass index, coronary artery disease, and type 2 diabetes was
associated with both early and later onset depression, while higher polygenic risk for
stroke was associated with later onset depression only. Significant genetic correla-
tions were found between body mass index and later onset depression, and between
coronary artery disease and both early and late onset depression. The phenotypic
associations between major depression and cardio-metabolic traits may partly reflect
their overlapping genetic etiology irrespective of the age depression first presents.
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1 | INTRODUCTION
Major depressive disorder (MDD) and cardio-metabolic traits are both
major causes of morbidity and mortality in high-income countries. Epi-
demiological studies have shown a well-established association
between them (B. W. J. H. Penninx, 2017): MDD increases the risk of
cardio-metabolic disease onset and mortality, but cardio-metabolic dis-
ease itself can also increase risk of developing MDD. Specifically, a
meta-analysis of 124,509 individuals across 21 studies showed that
depression is associated with an 80% increased risk for developing cor-
onary artery disease (Nicholson, Kuper, & Hemingway, 2006). Mezuk
et al (Mezuk, Eaton, Albrecht, & Golden, 2008) showed that MDD
predicted a 60% increased risk of type 2 diabetes, while type 2 diabetes
predicted a 15% increased risk in MDD. MDD is associated with an
increased risk of developing stroke (HR 1.45) (Pan, Sun, Okereke,
Rexrode, & Hu, 2011), but meta-analyses have also shown that 30%
of stroke survivors suffered from MDD (Ayerbe, Ayis, Wolfe, &
Rudd, 2013; Hackett & Pickles, 2014). Risk factors for cardio-metabolic
disease, such as obesity, are also linked to depression. Milaneschi et al.
(Milaneschi, Simmons, van Rossum, & Penninx, 2018) showed a bidirec-
tional association between depression and obesity, where obesity
increases risk for depression and depression increases risk for subse-
quent obesity. A more detailed review of the comorbidity between
depression and cardio-metabolic traits is given in B. W. Penninx,
Milaneschi, Lamers, and Vogelzangs (2013).
Multiple mechanisms have been proposed to explain the associa-
tion between MDD and cardio-metabolic diseases, for example biologi-
cal dysregulation, or an unhealthy lifestyle (B. W. J. H. Penninx, 2017).
However, it remains unclear to what extend these mechanisms influ-
ence the association, as most studies examining the mechanisms were
based on epidemiological observational study designs. The association
between MDD and cardio-metabolic disease could also be due to
shared genetic factors. Twin studies have shown that genetic factors
contribute 40% of the variation in liability to both MDD (Sullivan,
Neale, & Kendler, 2000) and coronary artery disease (Polderman
et al., 2015; Schunkert et al., 2011), 72% to type 2 diabetes (Willemsen
et al., 2015), and 40–70% to BMI(Locke et al., 2015). No twin heritabil-
ity estimates are available for stroke, as such studies have very limited
numbers of twins. The most recent published GWAS for major depres-
sion, including 246,363 cases and 561,190 controls, identified 102 loci
that were significantly associated with major depression, highlighting
the highly polygenic nature of major depression(Howard et al., 2019).
The heritability for major depression based on single nucleotide poly-
morphisms (h2SNP) was estimated to be 8.9% on the liability scale,
based on a lifetime risk of 0.15. Similarly, recent efforts to identify com-
mon variants associated with cardio-metabolic disease have shown
these traits to be highly polygenic (Malik et al., 2018; Nikpay
et al., 2015; Scott et al., 2017; Yengo et al., 2018).
Several studies have shown genetic overlap between MDD and
cardio-metabolic traits, in particular with coronary artery disease (Wray
et al., 2018). Findings for other cardio-metabolic traits have been incon-
sistent. Previous studies have identified genetic overlap between MDD
and BMI using polygenic risk scores (PRS) (Milaneschi et al., 2017), but
not based on genetic correlations (Wong et al., 2018). However, more
recent GWAS studies now have the power to detect a genetic correla-
tion between MDD and BMI (Wray et al., 2018). Studies using twin
data also showed that the phenotypic association between MDD and
type 2 diabetes was partly due to genetic effects (Kan et al., 2016). This
finding has been replicated using a polygenic risk score approach
(Wong et al., 2019), but not using genetic correlations (Clarke
et al., 2016; Wong et al., 2019). The Brainstorm Consortium did not
find a significant genetic correlation between MDD and stroke (Anttila
et al., 2018), while Wassentheil-Smoller et al (Wassertheil-Smoller
et al., 2018) showed that higher polygenic risk for MDD was associated
with increased risk for stroke, in particular small vessel disease.
The inconsistency in results is likely due to differences in methodo-
logical approaches or in summary statistics, but could also be due to
the heterogeneity of MDD. MDD onset can occur at any stage of life,
but the factors associated with MDD are often age specific or age
restricted (Power et al., 2017). Increased genetic risk for major depres-
sion is associated with earlier age at onset (AAO) compared with later
AAO (Wray et al., 2018). Earlier AAO MDD has a higher heritability and
is associated with increased risk for MDD in relatives. On the other
hand, vascular disease and its risk factors are linked to a later AAO for
MDD (G. S. Alexopoulos et al., 1997; Naismith, Norrie, Mowszowski, &
Hickie, 2012; Taylor, Aizenstein, & Alexopoulos, 2013). A large study of
Swedish twins showed that a later AAO for MDD in one twin was asso-
ciated with a higher risk for vascular disease in the other twin (Kendler,
Fiske, Gardner, & Gatz, 2009). To date, no molecular genetic studies
have examined the association between late onset MDD and cardio-
metabolic traits and in the current study we have more power to repli-
cate and further investigate this association leveraging both summary
statistics and common genetic variant information.
The main aim of the present study is to examine the genetic asso-
ciation between MDD and cardio-metabolic traits using PRS and
genetic correlations. Secondly, we will examine the association strati-
fied by AAO for MDD to test whether a higher genetic predisposition
for cardio-metabolic traits is associated with a later AAO for MDD.
2 | METHODS AND MATERIALS
2.1 | Samples
This study was performed using data from the Psychiatric Genomics
Consortium (PGC) MDD working group (PGC-MDD), Generation
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Scotland: The Scottish Family Health Study (GS:SFHS), and UK
Biobank.
2.1.1 | PGC
Full details of the studies that form the PGC-MDD have previously been
published (Wray et al., 2018). In summary, a subset of 11 studies from
the full PGC-MDD analysis were included in the current study, based on
the availability of AAO for MDD. All cases were required to have a lifetime
diagnosis of MDD based on international consensus criteria (DSM-IV,
ICD-9, or ICD-10)(American Psychiatric Association, 1994; World
Health Organization, 1978, 1992). This was ascertained using struc-
tured diagnostic instruments from direct interview by trained inter-
viewers or clinician administered checklists. In most studies (10/11),
controls were randomly selected from the general population and were
screened for absence of lifetime MDD. This led to a total of 9,518
cases and 11,557 controls with genotype data and AAO information.
2.1.2 | GS:SFHS
GS:SFHS is a family-based study consisting of 23,690 participants rec-
ruited from the population via general medical practices across Scot-
land. Sample characteristics and recruitment protocols have been
described elsewhere (B. H. Smith et al., 2013; Smith et al., 2006). In
summary, MDD diagnosis was based on the structured clinical inter-
view for DSM-IV disorders (SCID) (First, Spitzer, Gibbon, &
Williams, 1997). Participants who answered positively to two mental
health screening questions were invited to complete the full SCID to
ascertain MDD diagnosis. Cases were further refined through NHS
linkage. Controls were defined as participants who answered nega-
tively to the two screening questions or participants who did com-
plete the SCID but did not meet criteria for MDD. This resulted in
1947 cases and 4,858 controls, based on unrelated individuals.
2.1.3 | UK Biobank
UK Biobank is a large resource for identifying determinants of dis-
eases in middle aged and older healthy individuals (www.ukbiobank.
ac.uk) (Sudlow et al., 2015). A total 502,655 community-dwelling par-
ticipants aged between 37 and 73 years were recruited between
2006 and 2010 in the United Kingdom, and underwent extensive
testing including mental health assessments. MDD status in UK Bio-
bank was derived from the online mental health questionnaire as pre-
viously described (Coleman et al., 2020; Davis et al., 2018). Briefly,
MDD cases were defined as individuals meeting lifetime criteria for
MDD based on questions from the Composite International Diagnos-
tic Interview. Individuals reporting previous self-reported diagnosis of
schizophrenia (or other psychosis) or bipolar disorder were excluded
as MDD cases. Controls were defined as individuals who did not have
any self-reported diagnosis of mental illness, did not take any anti-
depressant medications, had not previously been hospitalized with a
mood disorder, and did not meet previously defined criteria for a
mood disorder (D. J. Smith et al., 2013). For the current study, this led
to 29,475 cases and 51,243 controls.
2.2 | AAO
AAO was defined as follows, based on previous work by Power et al
(Power et al., 2017) developed to account for the substantial by-study
heterogeneity in the measure. Heterogeneity in AAO within the PGC
MDD cohorts has been extensively investigated. Responses depend
on the specific setting in which AAO is asked, and may reflect age at
first symptoms, first visit to general practitioner or first diagnosis)
(Power et al., 2017). Using cut offs for AAO (e.g., onset under 30) does
not capture the variance in this measure, and we therefore followed
Power et al. (Power et al., 2017) to use the within study distribution
to define early and later onset depression. This approach assumes that
all cases were recruited from the same age at onset distribution with
differences due to study-specific parameters. Cases reporting AAO
older than the recorded age at interview were excluded from each
study. Within each study, cases were ordered by AAO and divided
into equal octiles (O1–O8). The first three octiles (O1–O3) were com-
bined into the early AAO group, the last three octiles (O6–O8) into
the late AAO group. Splitting into equal octiles can result in individuals
with the same AAO being arbitrarily placed in different octiles. To
address this, cases in O4 with the same AAO as the maximum AAO in
O3 were assigned to the early AAO group. Similarly, cases in O5 with
the same AAO as the minimum AAO in O6 were assigned to the late
AAO group. This led to a total of 15,844 MDD cases with early AAO
and 15,800 MDD cases with late AAO, and 67,532 controls.
2.3 | Genotyping and quality control
Genotyping procedures have been described in the original analysis for
each study (Bycroft et al., 2018; Nagy et al., 2017; Wray et al., 2018).
All analysis were based on individuals from European ancestry only.
PGC cohorts were genotyped following their local protocols. Indi-
vidual genotype data for all PGC cohorts was processed using the
PGC “Ricopili” pipeline for standardized quality control, imputation
and analysis (https://github.com/Nealelab/ricopili) (Lam et al., 2019).
Further details on the default parameters used for the current study
can be found in the Supplementary material.
For GS:SFHS, genotyping and imputation procedures have previ-
ously been published by Nagy et al (Nagy et al., 2017), a brief summary
can be found in the Supplementary Material. Monogenic variants and
variants with low imputation quality (INFO <0.4) were removed.
Two highly-overlapping custom genotyping arrays (UK BiLEVE
Axiom array and UK Biobank Axiom array, 800,000 markers) were
used to genotype all UK Biobank participants (N = 487,410) (Bycroft
et al., 2018). Detailed QC procedures are described in the Supplemen-
tary Material.
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2.4 | Statistical analysis
2.4.1 | PRS
Six PRS were calculated based on GWAS summary statistics for body
mass index (BMI), coronary artery disease (CAD) (Nikpay et al., 2015),
stroke and two stroke subtypes(Malik et al., 2018), and type 2 diabetes
(T2D)(Scott et al., 2017) based on external GWAS p-value <0.5. In
order to lower the multiple testing burden a p-value threshold of 0.5
was chosen, as often representative of the predictive ability, since R2
values often plateau across the range of p-values = .05–1. Table 1
provides further detail on the GWAS summary statistics.
PRS were calculated in all genotyped participants in each study
using PRSice v2 (https://github.com/choishingwan/PRSice) (Euesden,
Lewis, & O'Reilly, 2015). Prior to creating the scores, clumping was
used to obtain SNPs in linkage disequilibrium with an r2 < 0.25 within
a 250 kb window. Due to the large number of overlapping samples
between published BMI GWAS (Locke et al., 2015) and the PGC stud-
ies, a new GWAS was performed in the UK Biobank. The analysis
used BGENIE v1.2 (Bycroft et al., 2018)on 291,684 individuals in UK
Biobank that did not complete the Mental Health Questionnaire and
were therefore independent of prediction samples, as MDD case con-
trol status was defined from the Mental Health Questionnaire. The
Manhattan and QQ plot of the BMI GWAS can be found in the Sup-
plementary Figure 2.
Logistic regression was used to test the associations between the
six PRS and four different MDD case–control sets (all MDD cases
vs. control subjects, early AAO cases vs. control subjects, late AAO
cases vs. control subjects, and late AAO cases vs. early AAO cases).
These analyses test our two hypotheses; (a) testing the association of
genetic risk for cardiometabolic traits with MDD, and whether this
association differs by AAO by comparing controls and MDD cases (all
MDD cases vs. control subjects, early AAO cases vs. control subjects,
late AAO cases vs. control subjects), and (b) testing the association of
genetic risk for cardiometabolic traits with MDD AAO itself, by com-
paring late AAO cases vs. early AAO cases only. Analyses were per-
formed separately for each study, adjusting for relevant covariates in
each study (PGC & GS:SFHS: 5 genetic principal components for pop-
ulation stratification; UK Biobank: 6 genetic principal components for
population stratification, assessment center, and genotyping batch).
All PRS were standardized with each study across samples. Meta-
analyses of the results across studies for each PRS—MDD subtype
combination were then conducted to synthesize the findings for maxi-
mum statistical power and to check for heterogeneity. Fixed-effects
models were used in which the standardized regression coefficients
were weighted by the inverse of their squared SE. We tested for the
presence of between-study heterogeneity using Cochran's Q. We
corrected for multiple testing across all 24 meta-analysis models
(4 phenotypes × 6 PRS) using the Benjamini Hochberg false discovery
rate method(Benjamini & Hochberg, 1995), using a critical p-value
of .0026, which means that all p-values equal to or below the critical
p-value are considered significant.
2.4.2 | GWAS meta-analysis and genetic
correlations
Genome wide association analyses for three AAO-stratified MDD
case–control subsets were performed within each study, with adjust-
ments for population stratification. Study-specific covariates—for
example, site or familial relationships—were also fitted as required
(see Supplementary Material). The GWAS for GS:SFHS included all
individuals (compared with unrelated individuals in the PRS analysis)
to maximize power. Quality control of the study-level summary statis-
tics was performed using the EasyQC software (Winkler et al., 2014),
which implemented the exclusion of SNPs with imputation quality
<0.8 and minor allele count <25. p-value based meta-analyses, with
genomic control, were then performed for each of the three outcome
measures, using the METAL package (Willer, Li, & Abecasis, 2010).
SNPs with a combined sample size of less than 1,000 participants
were excluded.
Genetic correlations between the cardio-metabolic traits and the
four MDD summary statistics were calculated using Linkage Disequilib-
rium score regression (LDSC) (B. K. Bulik-Sullivan et al., 2015) using the
default HapMap LD reference. To maximize power (and given genetic
correlation analyses in LDSC are robust to sample overlap), the largest
available summary statistics were used. These included the previously
described summary statistics for coronary artery disease (Nikpay
et al., 2015), stroke (Malik et al., 2018), and type 2 diabetes (Scott
et al., 2017), as well as summary statistics for major depression from the
PGC-MDD and 23andMe GWAS, including UK Biobank (Wray
et al., 2018), and the most recent BMI GWAS, including both UK
TABLE 1 Information about GWAS summary statistics, based on European individuals only, to create polygenic risk scores in PGC-MDD, GS:
SFHS, and UK Biobank
Trait Origin N cases/N controls SNPs with p-value <5*10−8
Body mass index UK Biobank 291,683 individuals 27,164
Coronary artery disease CARDIoGRAM (Nikpay et al., 2015) 60,801 cases—123,504 controls 2,213
Stroke: All MEGASTROKE (Malik et al., 2018) 40,585 cases—406,111 controls 371
Stroke: Ischaemic MEGASTROKE (Malik et al., 2018) 34,217 cases—406,111 controls 307
Stroke: Small vessel disease MEGASTROKE (Malik et al., 2018) 5,386 cases—406,111 controls 0
Type 2 diabetes DIAGRAM (Scott et al., 2017) 26,676 cases—132,532 controls 1,788
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Biobank and the GIANT consortium (Yengo et al., 2018). All results were
corrected for multiple testing using the Benjamini Hochberg false discov-
ery rate method (critical p-value = .0064). Differences between genetic
correlations were assessed using block-jackknife (Supplementary Mate-
rial) (B. Bulik-Sullivan et al., 2015; Quenouille, 1956; Tukey, 1958).
3 | RESULTS
3.1 | Summary of AAO
The total sample consisted of 40,940 cases, including 15,844 cases
classified as early AAO, 15,800 cases as late AAO, 6296 general cases
not included in AAO-specific analysis, and 67,532 controls. The mean
AAO (SD) across samples was 32.36 (15.22) years. The mean AAO per
study ranged from 21.22 to 37.23 years, with the German PGC-MDD
samples, GS:SFHS and UK Biobank having a higher mean AAO
(Table S1). Figure 1 shows the distribution of AAO and the stratifica-
tion in the early and late AAO groups in each of the studies. Figure S1
shows the cumulative distribution of AAO in each study.
3.2 | Polygenic risk analysis of cardio-metabolic
disease
The meta-analyses across studies showed that PRS for BMI, coronary
artery disease, all stroke, ischaemic stroke, small vessel disease, and
type 2 diabetes were significantly associated with MDD case control
F IGURE 1 Distribution of Age at
onset for MDD per sample.
Scatterplot represents the
stratification of the early and late
AAO groups within each sample
[Color figure can be viewed at
wileyonlinelibrary.com]
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status (Figure 2, Table S2). Study specific results can be found in
Table S3.
When stratifying by AAO and comparing with controls, higher PRS
for BMI was more strongly associated with late AAO (OR = 1.07, 95%
CI = 1.06–1.09, p = 4.10 × 10−15) than early AAO (OR = 1.05, 95%
CI = 1.03–1.07, p = 2.60 × 10−7), however, the difference between
them was not significant (Figure 2). No significant difference was found
between BMI PRS and late versus early AAO within MDD cases
(OR = 1.02, 95% CI = 1.00–1.05, p = .04). Higher PRS for CAD was
associated with both late (OR = 1.05, 95% CI = 1.03–1.07,
p = 8.66 × 10−7) and early AAO (OR = 1.05, 95% CI = 1.03–1.07,
p = 1.50 × 10−7) compared with controls, while no significant differ-
ence was found between late and early AAO in MDD cases only
(OR = 1.00, 95% CI = 0.97–1.02, p = .776). Higher PRS for all stroke
was only associated with late AAO compared with controls (OR = 1.03,
95% CI = 1.01–1.05, p = .0006). Higher PRS for type 2 diabetes was
associated with both late (OR = 1.03, 95% CI = 1.01–1.05, p = .001)
and early (OR = 1.03, 95% CI = 1.01–1.05, p = .0004) AAO compared
with controls, the association between late and early AAO in MDD
cases only was nonsignificant (OR = 1.00, 95% CI = 0.97–1.02, p = .82).
3.3 | Genetic correlations with cardio-metabolic
traits
Genetic correlations were calculated between MDD and cardio-
metabolic traits based on the largest available GWAS (Figure 3,
Table S4). Significant genetic correlations were identified between
MDD and BMI (rg = 0.13, SE = 0.02, p = 3.43 × 10
−11), coronary artery
disease (rg = 0.12, SE = 0.03, p = 8.47 × 10
−6), and type 2 diabetes
(rg = 0.11, SE = 0.03, p = .0001). The genetic correlation between
ischaemic stroke and MDD was 0.10 (SE = 0.04, p = .026), however
this correlation did not survive the correction for multiple testing
(p < = .0064). No significant genetic correlations were identified for all
stroke and small vessel disease.
In order to calculate genetic correlations between the AAO strati-
fied MDD traits and cardio-metabolic traits, we ran GWAS on the
AAO stratified traits. Figure S3–S5 shows the Manhattan and QQ
plots for these traits. Table S4 provides further detail on the heritabil-
ity estimates of the stratified MDD traits. One genome-wide signifi-
cant variant was identified in the GWAS for early AAO versus
controls (rs2789313 on chromosome 10, Z-score = 5.56,
p = 2.74 × 10−8). This variant is located in the MALRD1 gene, which is
involved in hepatic bile acid metabolism and lipid homeostasis
(Vergnes, Lee, Chin, Auwerx, & Reue, 2013). This gene has not previ-
ously been associated with depression. Figure S3 shows a locus zoom
plot of the region on chromosome 10 including rs2789313.
Tables S5–S7 provide summary statistics on all suggestive
(p < 1 × 10−5) variants for the stratified GWAS.
The results for the stratified AAO traits showed a significant
genetic correlation between BMI and late AAO versus controls
(rg = 0.19, SE = 0.04, p = 2.42 × 10−5), no significant genetic correla-
tions were identified for either early AAO versus controls (rg = 0.05,
SE = 0.03, p = .059) or late versus early AAO (rg = 0.11, SE = 0.05,
F IGURE 2 Meta-analysis of associations between cardio-metabolic PRS and stratified MDD outcomes. OR, Odds Ratio; 95% CI, 95%
confidence interval; PRS, polygenic risk score, *p-value <.0264 [Color figure can be viewed at wileyonlinelibrary.com]
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p = .037). A stronger genetic correlation was found between late AAO
and CAD (rg = 0.19, SE = 0.06, p = .002) compared with early AAO
and CAD (rg = 0.11, SE = 0.04, p = .006), however, the difference
between the two genetic correlations was nonsignificant (block jack-
knife test for comparison of rg p = .227). No significant genetic corre-
lations were found between any of the AAO stratified MDD
outcomes and all stroke, ischaemic stroke, small vessel disease, or
type 2 diabetes (Figure 3, Table S4).
4 | DISCUSSION
This study explored whether the association between MDD and
cardio-metabolic traits is partly due to genetic factors. Using data
from publicly available GWAS and from the PGC, UK Biobank, and
Generation Scotland, we showed significant genetic overlap between
MDD and BMI, coronary artery disease, and type 2 diabetes from PRS
and genetic correlations.
Coronary artery disease and type 2 diabetes showed similar pat-
terns of association. Both were associated with MDD in general and
with late and early AAO, however, the association with late versus early
AAO was null. This indicates that both traits are associated with MDD
irrespective of the AAO, and not associated with AAO itself. The cur-
rent study is based on an extension of the strategies applied by Power
et al. (Power et al., 2017), who showed significant associations between
polygenic risk for coronary artery disease and MDD, as well as with
early and late onset MDD compared with controls. The results in the
current study are based on a larger sample and more recent effect esti-
mates for coronary artery disease, and have therefore greater power to
detect an effect. A recent study by Khandaker et al. (2019) did not find
a significant association between depression and coronary artery dis-
ease polygenic risk in UK Biobank. The effect sizes were similar to our
study, but the depression phenotype was based on the definition as
described by D. J. Smith, Nicholl, et al. (2013), and has lower heritability
than the Mental Health Questionnaire phenotype used here (Cai
et al., 2020; D. J. Smith, Nicholl, et al., 2013). This difference in results
is likely due to power: based on the heritability, sample size, and disease
prevalence, our study has 60% power to detect an association between
depression and coronary artery disease, compared with 18% in
Khandaker et al. (2019) (Dudbridge, 2013).
This is the first study to show genetic overlap between MDD and
type 2 diabetes using both PRS and genetic correlations. Twin studies
have previously shown genetic overlap between MDD and type 2 dia-
betes, but evidence from genetic studies has been weaker. The current
study, however, does show evidence for a shared genetic etiology
between MDD and type 2 diabetes based on both PRS and genetic cor-
relations (Clarke et al., 2016; Kan et al., 2016; Wong et al., 2019).
The polygenic risk score analysis showed that individuals with a
stronger genetic liability for stroke (and its subtypes) were more likely
to suffer from MDD. Clinical and neuroimaging studies have shown
that stroke could predispose the development of MDD by disrupting
frontostriatal circuits in the brain involved in mood regulation (George
S. Alexopoulos, 2017; Herrmann, Le Masurier, & Ebmeier, 2008; van
Sloten et al., 2015), specifically in older individuals with MDD or those
F IGURE 3 Genetic correlations (SE), derived using LD score regression, between cardio-metabolic traits and stratified MDD outcomes.
*p-value <.0064 [Color figure can be viewed at wileyonlinelibrary.com]
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with a later AAO for MDD. We did not find a significant association
between genetic risk for stroke and AAO. This could be due to a lack
of power, as the stroke outcomes had low heritability estimates
(observed h2  1%, Table S4B) and the sample size of the stratified
MDD outcomes is smaller than the overall MDD case–control
comparison.
When stratifying by AAO, higher polygenic risk for BMI was more
strongly associated with late AAO than early AAO compared with
controls, while a significant genetic correlation was only found
between late AAO versus control and BMI. A causal association using
Mendelian randomization has previously been identified between
BMI and depression, showing a 1.12 fold increase in depression for
each SD increase in BMI (Wray et al., 2018). Similarly, Vogelzangs et al
(Vogelzangs et al., 2010) have shown that over a 5 year period both
overall and abdominal obesity were associated with an increased risk
for MDD onset in men. Although the differences observed in this
study are not significant following multiple testing correction, in the
context of previous findings, they tentatively suggest that the etiolog-
ical processes underlying later onset MDD are linked to vascular
pathology and its risk factors such as obesity.
LD score regression produced fewer significant associations than
the polygenic risk score analysis. Genetic correlations using LD score
regression are based on summary statistics only and could therefore
be less powerful than a polygenic risk score approach based on raw
genotype data. However, the direction of effect was the same across
both analysis approaches and significant genetic correlations were
corroborated by significant polygenic risk score associations.
The current study has a number of limitations. The measures for
AAO for MDD rely on self-report and are assessed differently across
cohorts. We addressed this by stratifying AAO into octiles relative to
the mean in each study, therefore assuming that each study recruited
AAO from the same distribution with differences between studies
due to differences in ascertainment measure. It should be noted that
the mean AAO for late onset cases was 47.85 years, which is below
what is generally considered to be late onset or geriatric depression
(onset >60 years). More pronounced overlap might exist between late
onset MDD and cardio-metabolic traits when focusing on cases with
a later AAO, however this study only had a small number of these
included. However, this study does show that the effect of genetic
risk for somatic conditions on depression is not limited to late onset
or geriatric depression. By standardizing the PRS in all models we
have possibly introduced bias into our results. When the sample prev-
alence of a trait is not equal to the population prevalence, the mean
of the PRS will not represent the mean of the PRS in the population,
and thus introducing bias which could lead to inflated effect
estimates.
Future studies could focus on the effects of medication or disease
status for the cardio-metabolic traits, as the current study was unable
to adjust for this due to lack of information on these variables. Path-
way analysis might provide further insight into the biology underlying
the association between cardio-metabolic traits and MDD. In order to
further dissect the comorbidity between MDD and cardio-metabolic
disease, it is imperative to have cleaner phenotypes, in particular with
regard to AAO. Biobanks with electronic health records might aid in
providing improved phenotyping, but this still does not provide the
same information as one gets from clinical research studies.
In summary, this study showed genetic overlap between MDD
and cardio-metabolic traits based on PRS and genetic correlations.
These associations were largely irrespective of AAO for MDD, in par-
ticular for coronary artery disease and type 2 diabetes. The associa-
tion with BMI showed some evidence for a stronger link with later
onset MDD, however this finding needs to be replicated. Cardio-
metabolic traits and its risk factors are to open to preventative strate-
gies, therefore further understanding of the shared genetic etiology
between cardio-metabolic traits and MDD could play an important
role in the prevention or management of MDD.
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